Avelumab

Drug Profile

Avelumab

Alternative Names: Anti-PD-L1 monoclonal antibody - EMD Serono; Anti-PD-L1 monoclonal antibody - Merck; MSB-0010718C; PF-06834635

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator EMD Serono; Merck KGaA
  • Developer EMD Serono; Hospices Civils de Lyon; Merck KGaA; National Cancer Institute (USA); Pfizer; Syndax Pharmaceuticals; Vanderbilt-Ingram Cancer Center; Verastem
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Merkel cell carcinoma
  • Phase III Breast cancer; Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Urogenital cancer
  • Phase II Gestational trophoblastic disease; Glioblastoma; Nasopharyngeal cancer; Recurrent respiratory papillomatosis
  • Phase I/II Fallopian tube cancer; Peritoneal cancer
  • Phase I Hodgkin's disease; Solid tumours
  • Preclinical Acute myeloid leukaemia; Endometrial cancer
  • Phase Unknown Intestinal cancer; Peripheral T-cell lymphoma

Most Recent Events

  • 20 Feb 2017 Pfizer plans a phase I/II trial for Non-small cell lung cancer in USA (NCT03050554)
  • 10 Feb 2017 Phase-II clinical trials in Glioblastoma (Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT02968940)
  • 10 Feb 2017 Pfizer and University of Birmingham plans a phase II trial for Peripheral T-cell lymphoma (Second-line therapy or greater) in United Kingdom (NCT03046953)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top